News
К списку новостей
Lancet's team has achieved the inclusion of Zevtera in the List of Vital and Essential Drugs: a key step in the performance of Lancet's Mission and healthcare
A huge effort by all subdivisions of our company has made it possible to achieve a significant breakthrough: the antibiotic Zevtera was included in the List of Vital and Essential Drugs (VED). This success is not only a key milestone in the development of the company, but is also of great importance for the entire healthcare sector.
A new standard in the struggle for patient health
Zevtera is a new generation antibiotic developed with consideration to the acute problem of antibiotic resistance that threatens the entire world. The drug is intended, among other things, for the treatment of hospital-acquired pneumonia, which often affects severe patients in intensive care units. The possibility of prompt access to such an innovative drug is able to save many lives.
A journey lasting more than a year
The inclusion of the drug in the List of Vital and Essential Drugs was the result of careful and meticulous work of many subdivisions of the company. From the first steps of registration on the Russian market, through pharmacoeconomic studies, to the final defense at the commission: every detail of this process was completed with maximum attention.
However, the journey was difficult. In recent years, the procedure for including any drugs, especially foreign drugs, in the List of Vital and Essential Drugs has become much more complicated. Frequently, such applications require reconsideration, but our team succeeded at the first attempt.
Difficulties were overcome thanks to well-consolidated work
At the final stage of inclusion in the List of Vital and Essential Drugs, we managed to overcome many barriers. At the commission meeting, which lasted for an hour and a half, our drug faced ferocious debates. Subject to the current economic restrictions and high budget burden, making a decision was extremely difficult. However, thanks to the joint efforts of marketers, the legal service, medical experts, the drug market access service and the security department, we achieved to present strong evidence of the importance of the drug. Key support was lent by leading specialists, including Professor R.S. Kozlov, who came down in favor of the vital necessity of the antibiotic.
National security in pharmaceuticals
The inclusion of Zevtera in the List of Vital and Essential Drugs is more than just a success for the company. It is a contribution to national security. The shortage of new antibiotics caused by international isolation and a decrease in their marketing authorization creates serious risks for healthcare. The introduction of Zevtera to the Russian market will allow physicians to have available new effective means of infection control.
We are proud of our team and the result
This achievement was made possible thanks to the full dedication of each member of our team. Our work was highly appreciated not only within the company, but also by leading players in the global pharmaceutical market. We entered the same league with the largest manufacturers, such as Novartis, Pfizer, Takeda, etc., proving that we can, just like them, successfully find new products from developers, register them, and enter them in authorization and approval lists.
We are sure that this success will become a starting point for new achievements. Not only the creation of a market for Zevtera, but also new breakthroughs in the field of launching our 27 drugs on the Russian and foreign markets are going to happen next. Together, we prove that our company is capable of overcoming any barriers and contributing to saving lives.
A new standard in the struggle for patient health
Zevtera is a new generation antibiotic developed with consideration to the acute problem of antibiotic resistance that threatens the entire world. The drug is intended, among other things, for the treatment of hospital-acquired pneumonia, which often affects severe patients in intensive care units. The possibility of prompt access to such an innovative drug is able to save many lives.
A journey lasting more than a year
The inclusion of the drug in the List of Vital and Essential Drugs was the result of careful and meticulous work of many subdivisions of the company. From the first steps of registration on the Russian market, through pharmacoeconomic studies, to the final defense at the commission: every detail of this process was completed with maximum attention.
However, the journey was difficult. In recent years, the procedure for including any drugs, especially foreign drugs, in the List of Vital and Essential Drugs has become much more complicated. Frequently, such applications require reconsideration, but our team succeeded at the first attempt.
Difficulties were overcome thanks to well-consolidated work
At the final stage of inclusion in the List of Vital and Essential Drugs, we managed to overcome many barriers. At the commission meeting, which lasted for an hour and a half, our drug faced ferocious debates. Subject to the current economic restrictions and high budget burden, making a decision was extremely difficult. However, thanks to the joint efforts of marketers, the legal service, medical experts, the drug market access service and the security department, we achieved to present strong evidence of the importance of the drug. Key support was lent by leading specialists, including Professor R.S. Kozlov, who came down in favor of the vital necessity of the antibiotic.
National security in pharmaceuticals
The inclusion of Zevtera in the List of Vital and Essential Drugs is more than just a success for the company. It is a contribution to national security. The shortage of new antibiotics caused by international isolation and a decrease in their marketing authorization creates serious risks for healthcare. The introduction of Zevtera to the Russian market will allow physicians to have available new effective means of infection control.
We are proud of our team and the result
This achievement was made possible thanks to the full dedication of each member of our team. Our work was highly appreciated not only within the company, but also by leading players in the global pharmaceutical market. We entered the same league with the largest manufacturers, such as Novartis, Pfizer, Takeda, etc., proving that we can, just like them, successfully find new products from developers, register them, and enter them in authorization and approval lists.
We are sure that this success will become a starting point for new achievements. Not only the creation of a market for Zevtera, but also new breakthroughs in the field of launching our 27 drugs on the Russian and foreign markets are going to happen next. Together, we prove that our company is capable of overcoming any barriers and contributing to saving lives.